E-LIB Suche - Ergebnisse für: Gou, Hongfeng

1

Efficacy and safety of fruquintinib dose‐escalation strateg..:

Tan, Sirui ; Zhang, Shunyu ; Zhou, Nan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10757135/. , 2023

Link: http://www.ncbi.nlm.nih...

2

Sintilimab plus nab-paclitaxel as second-line treatment for..:

Zhou, Nan ; Li, Xiaofen ; Yang, Yu...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405505/. , 2023

Link: http://www.ncbi.nlm.nih...

3

Optimum duration of extended adjuvant endocrine therapy in ..:

Hu, Qiancheng ; Ye, Daoli ; Xudong, Zhao...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124296/. , 2023

Link: http://www.ncbi.nlm.nih...

4

Pathological complete response to neoadjuvant tislelizumab ..:

Zhou, Nan ; Chen, Yuhong ; Huang, Qian...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992202/. , 2023

Link: http://www.ncbi.nlm.nih...

5

Identification of Immune Subtypes and Candidate mRNA Vaccin..:

Wei, Yuanfeng ; Zheng, Lingnan ; Yang, Xi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628581/. , 2023

Link: http://www.ncbi.nlm.nih...

6

PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy..:

Tan, Sirui ; Yu, Jing ; Huang, Qiyue..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709255/. , 2022

Link: http://www.ncbi.nlm.nih...

7

Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROT..:

He, Yihong ; Zan, Xin ; Miao, Junming...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489811/. , 2022

Link: http://www.ncbi.nlm.nih...

8

Durable response to the combination of pembrolizumab and na..:

Tan, Sirui ; Yu, Jing ; Huang, Qiyue...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742598/. , 2022

Link: http://www.ncbi.nlm.nih...

9

Study of SOX combined with intraperitoneal high‐dose paclit..:

Tu, Li ; Zhang, Weihan ; Ni, Lu...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972103/. , 2022

Link: http://www.ncbi.nlm.nih...

10

Complete Pathologic Response After Concurrent Treatment wit..:

Yang, Jian ; Bi, Feng ; Gou, Hongfeng
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053529/. , 2021

Link: http://www.ncbi.nlm.nih...

11

Bevacizumab Combined with S‐1 and Raltitrexed for Patients ..:

Chen, Ye ; Zhou, Yu‐Wen ; Cheng, Ke...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342567/. , 2021

Link: http://www.ncbi.nlm.nih...

12

Rare DNA Mismatch Repair-Related Protein Loss in Patients w..:

Yu, Jing ; Zhang, Xi ; Huang, Qiyue...
info:eu-repo/semantics/altIdentifier/doi/10.2147/CMAR.S304281. , 2021

Link: https://www.dovepress.co..

13

Complete Pathologic Response After Concurrent Treatment wit..:

Yang, Jian ; Bi, Feng ; Gou, Hongfeng
info:eu-repo/semantics/altIdentifier/doi/10.2147/OTT.S298333. , 2021

Link: https://www.dovepress.co..

14

Rare DNA Mismatch Repair-Related Protein Loss in Patients w..:

Yu, Jing ; Zhang, Xi ; Huang, Qiyue...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183674/. , 2021

Link: http://www.ncbi.nlm.nih...

15

Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adju..:

Zhu, Yue-Ting ; Chen, Xin-Zu ; Chen, Ye...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726419/. , 2020

Link: http://www.ncbi.nlm.nih...